Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selinexor + bendamustine + rituximab
- Development stage
- Unknown
- Lead developer
- Karyopharm Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Selinexor + bendamustine + rituximab is an investigational combination therapy composed of: - **Selinexor**: an oral, selective inhibitor of exportin 1 (XPO1), leading to retained nuclear tumor suppressor proteins and apoptosis of malignant cells. - **Bendamustine**: a synthetic alkylating agent with antimetabolite properties, inducing DNA crosslinking and cell death. - **Rituximab**: a monoclonal antibody targeting CD20 on B lymphocytes, mediating antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. This combination is under evaluation as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies, showing potential synergistic and additive antitumor effects in preclinical and early clinical studies[2][4][7]. **Main mechanism of action:** antineoplastic, targeted B-cell depletion, DNA crosslinking, and inhibition of nuclear export.
- Other names
- selinexor + bendamustine + rituximab
02
Targets
Beyond the preview
Go deeper on selinexor + bendamustine + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selinexor + bendamustine + rituximab.